Pfenex Inc (PFNX) Set to Announce Quarterly Earnings on Thursday
Pfenex Inc (NYSEMKT:PFNX) will announce its earnings results after the market closes on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.
Pfenex (NYSEMKT:PFNX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). Pfenex had a negative return on equity of 75.61% and a negative net margin of 406.87%. The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.10 million. During the same quarter last year, the firm earned ($0.43) EPS. The company’s revenue was down 3.5% on a year-over-year basis.
Pfenex Inc (NYSEMKT PFNX) opened at $3.14 on Tuesday. Pfenex Inc has a twelve month low of $2.54 and a twelve month high of $11.35.
A number of brokerages recently commented on PFNX. Zacks Investment Research raised shares of Pfenex from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, October 24th. William Blair reaffirmed an “ourperform” rating on shares of Pfenex in a report on Friday, September 8th. Finally, ValuEngine downgraded shares of Pfenex from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.